Q1 2026 Syngene International Ltd Earnings Call Transcript
Key Points
- Syngene International Ltd (BOM:539268) reported an 11% increase in revenue from operations year-on-year, with a 7% increase in constant currency.
- The company successfully operationalized Unit 3, its biologics facility in Bengaluru, delivering a GMP clinical batch for a US-based client.
- Syngene has integrated automation into its DMPK operations, reducing turnaround times from five days to three days and enhancing cost efficiency by 30%.
- The company has strengthened its leadership team with the appointment of three industry professionals, enhancing its strategic and operational capabilities.
- Syngene was recognized by Time Magazine as the number 1 sustainable company in the pharma and biotech sector in India and among the top 500 most sustainable companies globally.
- The global CRO market faces continued uncertainty in the biotech funding environment, which has not yet stabilized or returned to pre-pandemic levels.
- The company's CDMO business was affected by milestone shifts, impacting the stability of small molecule development and manufacturing services.
- There is an ongoing inventory adjustment in the biologics commercial manufacturing business, which is expected to impact growth throughout the year.
- Employee costs increased by 15% year-on-year, driven by merit increases and staffing plans.
- The company experienced a hedge loss of INR4.8 crores, up from INR3.3 crores in the previous year, due to differences between average spot rates and hedge rates.
Portions of this transcript marked (technical difficulty) indicate audio problems. The missing text will be supplied if a replay becomes available.
Ladies and gentlemen, good day, and welcome to Q1 FY26 Financial Results Conference Call of Syngene International Limited. (Operator Instructions) I now hand the conference over to Ms. Nandini Agarwal. Thank you, and over to you, ma'am.
On, everyone. Thank you for joining us on this call to discuss Syngene's First Quarter Results for Financial Year 2026. To discuss the financial and business performance for the period we have on this call today, Mr. Peter Bains, Syngene's Managing Director and Chief Executive Officer; and Mr. Deepak Jain, Chief Financial Officer.
After the opening remarks, Peter and Deepak will be happy to answer any questions you might have. Before we begin, I would like to caution that comments made during this conference call today, we contain certain forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
